Shares of Healthcare sector company Ginkgo Bioworks moved -12.2% today, and are now trading at a price of $2.04. The mid-cap stock's daily volume was 34,627,619 compared to its average volume of 24,408,554. The S&P 500 index returned a -0.6% performance.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platforms for cell programming. The company is based in Boston and has 641 full time employees. Its market capitalization is $3,950,381,312.
8 analysts are following Ginkgo Bioworks and have set target prices ranging from $3 to $14.5 per share. On average, they have given the company a rating of buy. At today's prices, DNA is trading -72.33% away from its average analyst target price of $7.36 per share.
Over the last year, DNA shares have gone down by -80.6%, which represents a difference of -64.8% when compared to the S&P 500. The stock's 52 week high is $13.74 per share and its 52 week low is $1.96. Ginkgo Bioworks has averaged free cash flows of $-190,290,666.7 over the last four years, with a mean growth rate of -124.9%. It is likely that the stock will keep following its current negative performance trend while the underlying business is experiencing such poor cash flows.
For a deeper fundamental analysis into Ginkgo Bioworks and other market moving stocks, subscribe to our free newsletter today!
